These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 9241369)

  • 41. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
    Haddad R; Colevas AD; Tishler R; Busse P; Goguen L; Sullivan C; Norris CM; Lake-Willcutt B; Case MA; Costello R; Posner M
    Cancer; 2003 Jan; 97(2):412-8. PubMed ID: 12518365
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Taxanes as radiosensitizers for head and neck cancer.
    Herscher LL; Cook J
    Curr Opin Oncol; 1999 May; 11(3):183-6. PubMed ID: 10328592
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemotherapy in metastatic non-small-cell lung cancer.
    Sandler A
    Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):15-27. PubMed ID: 10981287
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of taxanes in the management of bladder cancer.
    Galsky MD
    Oncologist; 2005; 10(10):792-8. PubMed ID: 16314289
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study.
    Koukourakis MI; Bizakis JG; Skoulakis CE; Kyrmizakis D; Giatromanolaki A; Papadakis CE; Prokopakis E; Amanakis Z; Hellidonis ES
    Anticancer Res; 1999; 19(3B):2305-9. PubMed ID: 10472349
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The present and future of combination chemotherapy in bladder cancer.
    Culine S
    Semin Oncol; 2002 Jun; 29(3 Suppl 9):32-9. PubMed ID: 12094336
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Gemcitabine and breast cancer].
    Besse B; Spano JP
    Bull Cancer; 2002 Aug; 89 Spec No():S107-14. PubMed ID: 12449040
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
    Tumolo S; Toffoli G; Saracchini S; Lo Re G; Bruschi G; Boccieri MG
    Lung Cancer; 2001 Dec; 34 Suppl 4():S37-46. PubMed ID: 11742701
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Association of taxanes and radiotherapy: preclinical and clinical studies].
    Hennequin C
    Cancer Radiother; 2004 Nov; 8 Suppl 1():S95-105. PubMed ID: 15679254
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Metastatic breast cancer: new chemotherapy regimens with taxanes].
    Lopez M
    Clin Ter; 2005; 156(6):311-5. PubMed ID: 16463568
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
    Colevas AD; Busse PM; Norris CM; Fried M; Tishler RB; Poulin M; Fabian RL; Fitzgerald TJ; Dreyfuss A; Peters ES; Adak S; Costello R; Barton JJ; Posner MR
    J Clin Oncol; 1998 Apr; 16(4):1331-9. PubMed ID: 9552034
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
    Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
    Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.
    Bunn PA
    Semin Oncol; 1999 Feb; 26(1 Suppl 4):25-30. PubMed ID: 10201518
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New options in the treatment of non-small cell lung cancer.
    Fossella F; Rigas JR; Belani CP
    Anticancer Drugs; 1999 Nov; 10 Suppl 1():S25-8. PubMed ID: 10630365
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [New neoadjuvant approaches using gemcitabine in non-small-cell lung cancer].
    Depierre A; Westeel V; Jacoulet P
    Bull Cancer; 2002 Aug; 89 Spec No():S76-9. PubMed ID: 12449034
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
    Tishler RB; Norris CM; Colevas AD; Lamb CC; Karp D; Busse PM; Nixon A; Frankenthaler R; Lake-Willcutt B; Costello R; Case M; Posner MR
    Cancer; 2002 Oct; 95(7):1472-81. PubMed ID: 12237916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.